Featured Article
The Pulmonary Hypertension Association (PHA) Scientific Sessions Planning Committee has announced Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products (DCaRP) in the Center for Drug Evaluation and Research of the Food and Drug Administration (FDA), as a speaker at PHA’s 2018 International PH Conference and Scientific Sessions. DCaRP is responsible
Prompted by recent successes in the field of oncology in precision medicine, the Pulmonary Hypertension Association’s (PHA) Scientific Sessions Committee has invited Sagar Lonial, M.D., FACP, an internationally-recognized leading authority in multiple myeloma treatment and research, to provide his insight in the field of PH to health care providers. Dr. Lonial’s research has focused
A new molecular mechanism in the development of World Health Organization (WHO) Group 1 pulmonary hypertension (PH) – pulmonary arterial hypertension (PAH) – has been discovered by investigators from the Brigham and Women’s Hospital, through work funded in part by the Pulmonary Hypertension Association (PHA). NEDD9, a protein that was discovered in 1992 and has
This article by Emily K. Outtarac, Administrative Assistant, Medical Services, first appeared in Issue 1 2018 of Pathlight magazine. Become a member of PHA to receive this quarterly publication full of patient profiles, medical information and tips for living with pulmonary hypertension. The PHA Support Group program offers in-person meetings to exchange tips, learn
PHA News periodically runs Q&A style profiles of pulmonary hypertension (PH) health care professionals and programs that are participating in PHA’s 2018 International PH Conference and Scientific Sessions. By Susie McDevitt, NP Tell us your program’s name and a little about your staff. University of Michigan (UM) Pulmonary Hypertension Program The University of Michigan pulmonary
The Pulmonary Hypertension Association (PHA) hosted a lunch briefing in Washington, DC, Wednesday, June 6, for members of Congress and their staff. Oksana A. Shlobin, MD, FCCP, a director of the Pulmonary Hypertension Program at Inova Fairfax Hospital, educated attendees about pulmonary hypertension (PH), what it is and how it is treated. PH community
Steven H. Abman, M.D. David B. Frank, M.D., Ph.D. Stephanie Siehr Handler, M.D. Uyen Truong, M.D. Erika S. Berman Rosenzweig, M.D. Despite recent milestones in the field of pediatric PH, knowledge and treatment options still lag behind that of adult PH. This year’s
Because genetics are essential to the discussion about precision medicine, the Scientific Sessions Committee is excited to feature Michal Snyder, Ph.D., Stanford Ascherman professor and chair of Genetics and director of the Center of Genomics and Personalized Medicine at Stanford University School of Medicine, during the session block “Omics and Wearable in Pulmonary Hypertension:
Washington, D.C., Golden Glove Lightweight Champion and PHA celebrity champion Elvis Medrano will join the PH community at PHA’s 2018 International PH Conference and Scientific Sessions to share his battle with CTEPH during the opening session. Don’t miss out on meeting Elvis and also the opportunity to connect with other PH community members for
“Oh! My grandfather has hypertension!” Have you ever heard a response like this when trying to explain pulmonary hypertension (PH)? Members of Congress make laws that impact the PH community every day, but, like so many in the community, they are often unfamiliar with the challenges and seriousness of the disease. PHA’s Congressional Luncheon and
